The likelihood of developing HCC is higher in patients affected by NASH with cirrhosis than in patients with NAFLD [6]; an increased prevalence of HCC may be related to genetics, including the I148M variant of the PNPLA-3 gene, which represents a significant cause of mortality in NAFLD patients. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.